Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali Murat

Showing results (241-250 of 263) with videos related to

Pageof 27
Sort By:
Oncology|June 28, 2023
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated SurgicallyMurat Bardakci, Derya Demirtas Esmer, Emre Hafizoglu, et al.
Medicina (Kaunas, Lithuania)|June 27, 2025
Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from TurkeyGul Sema Yildiran Keskin, Ozge Yetginoglu, Sertac Vurgun, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|December 27, 2025
Impact of oral nutritional support adherence on muscle strength, body composition, and general health status in gastrointestinal cancer patients: ONMUS studyAhmet Ozveren, Timucin Cil, Derya Hopanci Bicakli, et al.
Journal of Cancer Research and Clinical Oncology|July 22, 2023
Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?Gürkan Güner, Burak Yasin Aktaş, Fatma Buğdaycı Başal, et al.
Medicina (Kaunas, Lithuania)|July 30, 2025
Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly PopulationsOzkan Alan, Tugba Akın Telli, Sinem Akbas, et al.
Medicine|December 23, 2022
Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology GroupMustafa Gürbüz, Saadettin Kiliçkap, Ahmet Bilici, et al.
American Journal of Cancer Research|February 9, 2026
Second-line nab-paclitaxel and gemcitabine for advanced pancreatic cancer following FOLFIRINOX: outcomes and insightsAysegul Merc Cetınkaya, Ali Murat Tatlı, Sabin Goktas Aydın, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 28, 2022
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancerYusuf Ilhan, Ali Murat Tatli, Fatih Teker, et al.
Cancers|January 25, 2025
Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning ApproachHakan Şat Bozcuk, Leyla Sert, Muhammet Ali Kaplan, et al.
Cancer Investigation|December 5, 2025
Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group StudyMukremin Uysal, Sezer Saglam, İsmail Beypınar, et al.
Pageof 27

Showing results (241-250 of 263) with videos related to

Sort By:
Pageof 27
Oncology|June 28, 2023
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated SurgicallyMurat Bardakci, Derya Demirtas Esmer, Emre Hafizoglu, et al.
Medicina (Kaunas, Lithuania)|June 27, 2025
Survival Outcomes in Metastatic Germ Cell Tumors: A Multicenter Study from TurkeyGul Sema Yildiran Keskin, Ozge Yetginoglu, Sertac Vurgun, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|December 27, 2025
Impact of oral nutritional support adherence on muscle strength, body composition, and general health status in gastrointestinal cancer patients: ONMUS studyAhmet Ozveren, Timucin Cil, Derya Hopanci Bicakli, et al.
Journal of Cancer Research and Clinical Oncology|July 22, 2023
Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?Gürkan Güner, Burak Yasin Aktaş, Fatma Buğdaycı Başal, et al.
Medicina (Kaunas, Lithuania)|July 30, 2025
Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly PopulationsOzkan Alan, Tugba Akın Telli, Sinem Akbas, et al.
Medicine|December 23, 2022
Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology GroupMustafa Gürbüz, Saadettin Kiliçkap, Ahmet Bilici, et al.
American Journal of Cancer Research|February 9, 2026
Second-line nab-paclitaxel and gemcitabine for advanced pancreatic cancer following FOLFIRINOX: outcomes and insightsAysegul Merc Cetınkaya, Ali Murat Tatlı, Sabin Goktas Aydın, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 28, 2022
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancerYusuf Ilhan, Ali Murat Tatli, Fatih Teker, et al.
Cancers|January 25, 2025
Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning ApproachHakan Şat Bozcuk, Leyla Sert, Muhammet Ali Kaplan, et al.
Cancer Investigation|December 5, 2025
Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group StudyMukremin Uysal, Sezer Saglam, İsmail Beypınar, et al.
Pageof 27